fr   en
Agreement

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2006-01-18
Biotech partner: Evotec (Germany)
Pharma Partner: Boehringer Ingelheim (Germany)
Type of agreement: * R&D
* other
Compound: therapeutic compounds acting on G-protein-coupled receptors
Disease area:  CNS, inflammation, cardiometabolic and respiratory diseases, oncology
Development phase:  
Nature of the agreement: extension of a 2004 R&D agreement

- On October 22, 2009, Evotec announced it has achieved another milestone in its research collaboration with Boehringer Ingelheim. The collaboration, which was initiated in August 2004, has up to now resulted in seven milestone payments. The achievement of the current milestone has led to a payment to Evotec of € 2.5 million. The milestone was achieved for the selection of a candidate compound for pre-development studies in a cardiometabolic program.

- On November 9, 2009 the two companies annouced that they extend and broaden their research collaboration.
The collaboration was initiated in August 2004 and has been extended on two previous occasions. At the same time, based on the success to date in the areas of CNS, inflammation, cardiometabolic and respiratory diseases the scope of the collaboration has been expanded to also include oncology targets. Over the term of the extension Evotec will receive research funding of around € 15 million plus success milestones and royalties.


Financial terms of the agreement: On November 9, 2009, the companies announced that strategic research collaboration continues for another 4 years at a value of € 15 million plus milestones and royalties.

- On 17 June 2010, Evotec has received a milestone as part of its research alliance with Boehringer Ingelheim and will receive a payment of € 2.5 million. The milestone was achieved for the selection of a candidate compound for pre-development studies in an oncology programme.

– On 4 August 2010, the research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of € 2.5 million to Evotec. The milestone reached was the selection of a candidate compound for pre-development studies in an inflammation and immunology programme.


Go back to previous page